Alcedis
Alcedis is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management The MINERVA Trial – A phase IV Trial
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification (NivoMela)
Sponsor Universitaetsklinikum Essen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
Sponsor SRH Wald-Klinikum Gera GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC
Sponsor TheraOp gGmbH
- Start (EU)
- Latest update
- Estimated end
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
Sponsor Goethe University Frankfurt
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC
Sponsor Rheinische Friedrich-Wilhelms-Universitaet Bonn
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Alcedis?
The 2026-10-09 snapshot links Alcedis to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Electronic data capture, Data management, Project management, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Alcedis?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Cardiology, Dermatology. Recorded phases include Phase 4, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Alcedis conducted?
The linked trials record locations in 4 countries, including Germany, Austria, Belgium, Italy. These are trial locations, not confirmed office locations or countries where Alcedis delivered services.
What can this page tell me about Alcedis's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Alcedis. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Alcedis GmbH